NCT02083666View on ClinicalTrials.gov

Safety and Tolerability of SOBI002 in Healthy Volunteers Following Single and Repeated Administration

PHASE1TerminatedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

November 30, 2014

Study Completion Date

February 28, 2015

Conditions
Healthy
Interventions
DRUG

SOBI002

Test Product

DRUG

Placebo

Reference product

Trial Locations (1)

SW17 0RE

Richmond Pharmacology Ltd., London

Sponsors
All Listed Sponsors
collaborator

Richmond Pharmacology Limited

INDUSTRY

lead

Swedish Orphan Biovitrum

INDUSTRY